743 related articles for article (PubMed ID: 18052601)
1. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH; Sheen CW; Fahey J; Zanin M; Tyssen D; Lima VD; Wynhoven B; Kuiper M; Sluis-Cremer N; Harrigan PR; Tachedjian G
PLoS Med; 2007 Dec; 4(12):e335. PubMed ID: 18052601
[TBL] [Abstract][Full Text] [Related]
2. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.
Radzio J; Yap SH; Tachedjian G; Sluis-Cremer N
AIDS; 2010 Mar; 24(5):659-67. PubMed ID: 20160634
[TBL] [Abstract][Full Text] [Related]
3. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.
Brehm JH; Koontz DL; Wallis CL; Shutt KA; Sanne I; Wood R; McIntyre JA; Stevens WS; Sluis-Cremer N; Mellors JW;
Clin Infect Dis; 2012 Sep; 55(5):737-45. PubMed ID: 22618567
[TBL] [Abstract][Full Text] [Related]
4. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
[TBL] [Abstract][Full Text] [Related]
5. The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
Xu HT; Colby-Germinario SP; Oliveira M; Han Y; Quan Y; Zanichelli V; Wainberg MA
J Virol; 2014 Feb; 88(3):1536-47. PubMed ID: 24227862
[TBL] [Abstract][Full Text] [Related]
6. Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing.
Götte M
PLoS Med; 2007 Dec; 4(12):e346. PubMed ID: 18052605
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.
Lengruber RB; Delviks-Frankenberry KA; Nikolenko GN; Baumann J; Santos AF; Pathak VK; Soares MA
J Antimicrob Chemother; 2011 Apr; 66(4):702-8. PubMed ID: 21393163
[TBL] [Abstract][Full Text] [Related]
8. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.
von Wyl V; Ehteshami M; Symons J; Bürgisser P; Nijhuis M; Demeter LM; Yerly S; Böni J; Klimkait T; Schuurman R; Ledergerber B; Götte M; Günthard HF;
J Infect Dis; 2010 Apr; 201(7):1054-62. PubMed ID: 20170373
[TBL] [Abstract][Full Text] [Related]
9. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
Paredes R; Puertas MC; Bannister W; Kisic M; Cozzi-Lepri A; Pou C; Bellido R; Betancor G; Bogner J; Gargalianos P; Bánhegyi D; Clotet B; Lundgren J; Menéndez-Arias L; Martinez-Picado J;
J Infect Dis; 2011 Sep; 204(5):741-52. PubMed ID: 21844300
[TBL] [Abstract][Full Text] [Related]
10. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
Hachiya A; Kodama EN; Sarafianos SG; Schuckmann MM; Sakagami Y; Matsuoka M; Takiguchi M; Gatanaga H; Oka S
J Virol; 2008 Apr; 82(7):3261-70. PubMed ID: 18216099
[TBL] [Abstract][Full Text] [Related]
11. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
[TBL] [Abstract][Full Text] [Related]
12. Subunit-specific mutational analysis of residue N348 in HIV-1 reverse transcriptase.
Radzio J; Sluis-Cremer N
Retrovirology; 2011 Aug; 8():69. PubMed ID: 21859446
[TBL] [Abstract][Full Text] [Related]
13. Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.
Price H; Asboe D; Pozniak A; Gazzard B; Fearnhill E; Pillay D; Dunn D; ;
Antivir Ther; 2010; 15(2):203-11. PubMed ID: 20386075
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms by which the G333D mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance to zidovudine and lamivudine.
Zelina S; Sheen CW; Radzio J; Mellors JW; Sluis-Cremer N
Antimicrob Agents Chemother; 2008 Jan; 52(1):157-63. PubMed ID: 17967907
[TBL] [Abstract][Full Text] [Related]
15. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V
J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076
[TBL] [Abstract][Full Text] [Related]
16. N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine.
Yap SH; Herman BD; Radzio J; Sluis-Cremer N; Tachedjian G
J Acquir Immune Defic Syndr; 2012 Oct; 61(2):153-7. PubMed ID: 22743599
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.
Hachiya A; Shimane K; Sarafianos SG; Kodama EN; Sakagami Y; Negishi F; Koizumi H; Gatanaga H; Matsuoka M; Takiguchi M; Oka S
Antiviral Res; 2009 Jun; 82(3):115-21. PubMed ID: 19428602
[TBL] [Abstract][Full Text] [Related]
18. N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.
Biondi MJ; Beilhartz GL; McCormick S; Götte M
J Biol Chem; 2010 Aug; 285(35):26966-26975. PubMed ID: 20530477
[TBL] [Abstract][Full Text] [Related]
19. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.
Ehteshami M; Beilhartz GL; Scarth BJ; Tchesnokov EP; McCormick S; Wynhoven B; Harrigan PR; Götte M
J Biol Chem; 2008 Aug; 283(32):22222-32. PubMed ID: 18547911
[TBL] [Abstract][Full Text] [Related]
20. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.
Schuckmann MM; Marchand B; Hachiya A; Kodama EN; Kirby KA; Singh K; Sarafianos SG
J Biol Chem; 2010 Dec; 285(49):38700-9. PubMed ID: 20876531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
